TIDMAGL
Angle PLC
28 November 2017
For immediate release 28 November 2017
ANGLE plc ("the Company")
PARSORTIX(TM) SYSTEM ENABLES MOLECULAR DETECTION AND
CHARACTERISATION OF CIRCULATING TUMOUR CELLS WHERE OTHER APPROACHES
FAIL
Results demonstrate that harvested CTCs can be analysed without
further purification steps
Study published in eighth peer reviewed paper detailing
Parsortix(TM) use
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy
company, today announces that its Parsortix(TM) system is the
subject of a further peer-reviewed publication in the journal
Oncotarget, detailing work undertaken by Prof. Robert Zeillinger's
Molecular Oncology Group at the Medical University of Vienna
(Vienna). Prof. Zeillinger is a key opinion leader in the field of
liquid biopsies use in oncology.
Prof Zeillinger's group developed and tested protocols to allow
the molecular characterisation of the circulating tumour cells
(CTCs) and residual blood cells harvested by the Parsortix(TM)
system without the need to separate out the CTCs. This was only
possible because the Parsortix(TM) system provides high purity
cells with very efficient removal of white blood cells. With
alternative approaches for CTC enrichment such as density gradient
centrifugation, this has not been possible, as high levels of
contaminating white blood cells remain with the CTCs captured.
Vienna had identified specific genes which were expressed
preferentially on CTCs earlier and, evaluating a panel of such
genes, were able to get positive results in 95% of primary (i.e.
localised disease that has not spread) gynaecological cancer
patient samples, 100% of recurrent gynaecological cancer patient
samples and 92% metastatic breast cancer patient samples.
This workflow established by Prof. Zeillinger's group provides
the opportunity not only for use in detection of cancer but also
the molecular characterisation of CTCs for the purpose of assessing
which drugs may be most effective for a patient during their
disease progression.
The publication is available at
https://angleplc.com/library/publications/
Professor Robert Zeillinger, Head of the Molecular Oncology
Group at the Medical University of Vienna, commented:
"In the study we have demonstrated that ANGLE's Parsortix(TM)
system addresses key limitations of other approaches for CTC liquid
biopsy through the combination of its sensitivity in isolating
circulating cancer cells in blood and the high purity of the
harvested cells enabling their direct molecular analysis."
ANGLE Founder and Chief Executive, Andrew Newland,
commented:
"This published study further demonstrates that the
Parsortix(TM) system outperforms other approaches for harvesting
circulating tumour cells from the blood of cancer patients in the
fast emerging liquid biopsy market. The capability to harvest
cancer cells with high purity to allow direct molecular analysis of
the cells strongly differentiates our system, which should
facilitate adoption in clinical practice."
For further information ANGLE:
ANGLE plc +44 (0) 1483 343434
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
finnCap Ltd (NOMAD and Joint
Broker)
Corporate Finance - Adrian
Hargrave, Simon Hicks, Kate
Bannatyne
Corporate Broking - Alice Lane,
Nikita Jain +44 (0)20 7220 0500
WG Partners (Joint Broker)
Nigel Barnes, Nigel Birks,
Andrew Craig, Chris Lee +44 (0) 203 705 9330
FTI Consulting
Simon Conway, Mo Noonan, Stephanie
Cuthbert +44 (0) 203 727 1000
Kimberly Ha (US) +1 212 850 5612
For Frequently Used Terms, please see the Company's website on
http://www.angleplc.com/the-parsortix-system/glossary/
Notes for editors
About ANGLE plc www.angleplc.com
ANGLE is a world leading liquid biopsy company with sample to
answer solutions. ANGLE's proven patent protected platforms include
an epitope-independent circulating tumor cell (CTC) harvesting
technology and a downstream analysis system for cost effective,
highly multiplexed analysis of nucleic acids and proteins.
ANGLE's cell separation technology is called the Parsortix(TM)
system and it enables a liquid biopsy (simple blood test) to be
used to provide the cells of interest. Parsortix is the subject of
granted patents in Europe, the United States, Canada, India, China,
Japan and Australia and three extensive families of patents are
being progressed worldwide. The system is based on a microfluidic
device that captures live cells based on a combination of their
size and compressibility. Parsortix has a CE Mark for Europe and
FDA authorisation is in process for the United States.
ANGLE's analysis technology for proteins and nucleic acids of
all types is based on a patented flow through array technology. It
provides for highly multiplexed, rapid and sensitive capture of
targets from a wide variety of sample types. A proprietary
chemistry allows for the capture and amplification of over 100
biomarkers simultaneously in a single reaction. These technologies
can be combined to provide fully automated, sample to answer
results in both centralized laboratory and point of use cartridge
formats. It is ideal for measuring gene expression and other
markers directly from Parsortix harvests.
ANGLE has established formal collaborations with world-class
cancer centres. These Key Opinion Leaders are working to identify
applications with medical utility (clear benefit to patients), and
to secure clinical data that demonstrates that utility in patient
studies. Details are available here
http://www.angleplc.com/the-company/collaborators/
The analysis of the cells that can be harvested from patient
blood with ANGLE's Parsortix(TM) system has the potential to help
deliver personalised cancer care offering profound improvements in
clinical and health economic outcomes in the treatment and
diagnosis of various forms of cancer.
The global increase in cancer to a 1 in 3 lifetime incidence is
set to drive a multi-billion dollar clinical market. The
Parsortix(TM) system is designed to be compatible with existing
major medtech analytical platforms and to act as a companion
diagnostic for major pharma in helping to identify patients that
will benefit from a particular drug and then monitoring the drug's
effectiveness.
As well as cancer, the Parsortix(TM) technology has the
potential for deployment with several other important cell types in
the future. ANGLE biomarker analysis platforms are adaptable to
measure protein and nucleic acid biomarkers across the full
spectrum of disease applications.
ANGLE stock trades on the AIM market of the London Stock
Exchange under the ticker symbol AGL and in New York on the OTC-QX
under the ticker symbol ANPCY. For further information please
visit: www.angleplc.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAZMMZMNNVGNZM
(END) Dow Jones Newswires
November 28, 2017 02:01 ET (07:01 GMT)
Angle (LSE:AGL)
Historical Stock Chart
From Apr 2024 to May 2024
Angle (LSE:AGL)
Historical Stock Chart
From May 2023 to May 2024